Teva Pharmaceutical Industries Aktie
WKN: 883035 / ISIN: US8816242098
05.05.2025 13:35:26
|
Teva, Alvotech Say FDA Approved Interchangeability For Stelara Biosimilar Across All Indications
(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), and Alvotech (ALVO) Monday said that the U.S. Food and Drug Administration (FDA) has approved Selarsdi as interchangeable with its reference product Stelara .
Selarsdi is approved for all indications matching the reference product, including the treatment of psoriatic arthritis and plaque psoriasis in patients 6 years and older, Crohns disease, and ulcerative colitis.
"Tevas recent launch of two biosimilars SELARSDI and EPYSQLI coupled with a rich pipeline of assets expected to launch over the next few years, position Teva to establish a strong leadership position in the growing landscape of biosimilars and to drive growth for the company as it embarks on the next phase of its strategy," said Thomas Rainey, Senior Vice President, U.S. Biosimilars at Teva.
"With two important biosimilars on the U.S. market and Biologics License Applications for three new biosimilar candidates under FDA review, Alvotech continues to rapidly expand its portfolio of high-quality biologics based on a fully integrated approach to development and manufacturing, coupled with a unique focus on biosimilars," said Anil Okay, Chief Commercial Officer for Alvotech.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Alvotech Registered Shsmehr Nachrichten
12.08.25 |
Ausblick: Alvotech Registered stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) | |
29.07.25 |
Erste Schätzungen: Alvotech Registered präsentiert Quartalsergebnisse (finanzen.net) | |
09.07.25 |
GNW-News: Alvotech erweitert seine Kapazitäten in den Bereichen Montage und Verpackung mit der Akquisition von Ivers-Lee in der Schweiz (dpa-AFX) | |
06.05.25 |
Ausblick: Alvotech Registered präsentiert Quartalsergebnisse (finanzen.net) | |
22.04.25 |
Erste Schätzungen: Alvotech Registered legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net) |
Analysen zu Alvotech Registered Shsmehr Analysen
Aktien in diesem Artikel
Alvotech Registered Shs | 6,94 | -3,07% |
|
Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 17,00 | 0,00% |
|